Tiksagewimab i cilgawimab a warianty budzące obawy (VOC)

1.AstraZeneca Pharmaceuticals LP. Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities [press release]. https://www.astrazeneca.com/media-centre/press- releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-  oxford-and-washington-universities.html. Published December 23, 2021. Accessed July 27, 2022; 2. Loo YM, McTamney  PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci Transl Med. 2022;14:eabl8124; 3. Dong J, Zost SJ, Greaney AJ, et al. Genetic and  structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021;6:1233-1244; 4. Han P, Li L, Liu S, et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell. 2022;185:630-640.e10; 5. Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2 Omicron  (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94:1738-1744; 6. Research Collaboratory for  Structural Bioinformatics PDB. Protein Data Bank. 7DF3. RCSB PDB website. https://www.rcsb.org/3d-view/7DF3. Structure  publication: Xu C et al. Sci Adv. 2021;7:eabe5575. Mol* Viewer: Sehnal D et al. Nucleic Acids Res. 2021;49:W431-W437. https://  doi.org/10.1093/nar/gkab314; 7. Henderson R, Edwards RJ, Mansouri K, et al. Controlling the SARS-CoV-2 spike glycoprotein  conformation. Nat Struct Mol Biol. 2020;27:925-933; 8. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat.  2011;10:128-134; 9. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.  Pharmacol Rev. 2003;55:597-606; 10. National Center for Advancing Translational Sciences. Evusheld: tixagevimab  (tixagevimab) and cilgavimab (cilgavimab) mAbs for SARS-CoV-2 antiviral resistance information (version 5). National Center for  Advancing Translational Sciences website. https://opendata.ncats.nih.gov/variant/datasets?id=107. Accessed July 27, 2022; 11. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184:2939-2954.e9; 12. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717-726; 13. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS- CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220-4236.e13; 14. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28:1297-1302; 15. VanBlargan LA, Errico JM, Halfmann  PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28:490-495; 16. Case JB, Mackin S, Errico J, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains [preprint published online March 18, 2022]. bioRxiv. 2022. https://doi.org/10.1101/2022.03.17.4847 87. Accessed July 27, 2022; 17. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection [published online ahead of print June 17, 2022]. Nature. 2022. https://doi.org/10.1038/s41586-022-04980-y. Accessed July 27, 2022; 18. Yamasoba D, Kimura I, Kosugi Y, et al. Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies [preprint published online July 15, 2022]. bioRxiv. 2022. https://www.biorxiv.org/content/10.1101/2022.07.14. 500041v1. Accessed July 27, 2022; 19. Cao Y, Yu Y, Song W, et al. Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA.2.75 [preprint published online July 19, 2022]. bioRxiv. 2022. https://doi.org/10.1101/ 2022.07.18.500332. Accessed July 27, 2022; 20. Tuekprakhon A, Huo J, Nutalai R, et al. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum [preprint published online May 23, 2022]. bioRxiv. 2022. https://www. biorxiv.org/content/10.1101/2022.05. 21.492554v1. Accessed July 27, 2022; 21. Touret F, Baronti C, Pastorino B, et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Sci Rep. 2022;12:12609; 22. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants [published online ahead of print July 20, 2022]. N Engl J Med. 2022. https://www.nejm.org/doi/10.1056/ NEJMc2207519. Accessed July 27, 2022.

Aktualną Charakterystykę Produktu Leczniczego Evusheld znajdziesz tutaj: https://www.astrazeneca.pl/content/dam/az-pl/SPC/SPC_Evusheld_2022-09-16.pdf